Business · 31/12/2024
FDA Renews Dermatologic and Ophthalmic Drugs Advisory Committee for 2 Years
The US Food and Drug Administration (FDA) is renewing the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on October 7, 2026.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →